Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE READY, a 56-Week Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study with Randomized Withdrawal

Saved in:
Bibliographic Details
Published inSkin (Milwood, N.Y.) Vol. 4; no. 6; p. s83
Main Authors Gordon, K, Foley, P, Krueger, JG, Pinter, A, Reich, K, Vender, R, Vanvoorden, V, Madden, C, Peterson, L, Blauvelt, A
Format Journal Article
LanguageEnglish
Published 27.10.2020
Online AccessGet full text

Cover

More Information
ISSN:2574-1624
2574-1624
DOI:10.25251/skin.4.supp.83